Tempest Therapeutics, Inc. has granted stock options to its director, Frederick John W., as part of its strategy to incentivize key personnel. The stock options, amounting to 25,000 shares, are priced at $0.74 each. This decision reflects the company's ongoing efforts to retain and motivate its leadership in the competitive pharmaceutical preparations industry.

Tempest Therapeutics, Inc. operates under the SIC code 2834, which encompasses pharmaceutical preparations. The company is publicly traded on the Nasdaq under the ticker symbol TPST. Recent filings indicate that the company is classified as a smaller reporting company and a non-accelerated filer.

The SEC filing, with accession number 0001213900-26-114957, provides details about the stock option grant. According to the filing, the options were granted on October 13, 2026, and will vest over a three-year period. One-third of the shares will vest on the first anniversary of the grant date, with the remaining shares vesting in equal monthly installments thereafter, contingent upon the reporting person's continued service.

This development may have implications for the company's employee retention strategies, particularly as the pharmaceutical industry continues to evolve. By offering stock options, Tempest Therapeutics aims to ensure that its key personnel are aligned with the company's long-term goals and performance.

The filing does not specify what happens next regarding further stock option grants or additional compensation strategies.